Filtering by:
Targeted TherapyFDA Approves Tibsovo (Ivosidenib) for Acute Myeloid Leukemia (AML)
The US Food and Drug Administration (FDA) has approved the targeted therapy drug Tibsovo (ivosidenib) to treat some adults with a certain type of acute myeloid leukemia (AML).
FDA Approves Drug Combination for Aggressive Type of Thyroid Cancer
The US Food and Drug Administration (FDA) has approved a combination of 2 targeted drugs to treat people with anaplastic thyroid cancer that has a certain type of gene mutation (BRAF V600E) and cannot be completely removed through surgery.
FDA Approves First Drug Specifically for BRCA-mutated Breast Cancer
The US Food and Drug Administration (FDA) has for the first time approved a treatment specifically for a type of breast cancer caused by a mutated BRCA gene: Lynparza (olaparib).
New Cancer Drug Approvals From 2017
In 2017, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
FDA Expands Approval for Sutent (Sunitinib) After Kidney Cancer Surgery
The US Food and Drug Administration (FDA) has approved Sutent (sunitinib) to treat adults who are at high risk of kidney cancer returning after they’ve had a nephrectomy, surgical removal of a kidney.
FDA Approves Calquence (Acalabrutinib) for Mantle Cell Lymphoma
The US Food and Drug Administration (FDA) has approved a targeted therapy for treating certain adults with mantle cell lymphoma.
FDA Approves Verzenio (Abemaciclib) for Certain Advanced Breast Cancers
The US Food and Drug Administration (FDA) has approved Verzenio (abemaciclib) for women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that is in an advanced stage and has gotten worse after hormone therapy treatment.
Adapting CAR T-Cell Therapy to Treat Neuroblastoma
With the success of the new drug, Kymriah, pediatric oncology researchers are trying to adapt CAR T-cell therapy to treat solid tumors, like neuroblastoma.